Investment in life sciences startups is on pace to set a record in 2018, with biotechnology related industries raising more than $4 billion in the second quarter alone. At the same time, the size of average seed stage deals is on the rise, indicating higher valuations for startups.
Join our panel of investors to learn their perspectives on opportunities for biotech and technology-based startups seeking capital, and what companies can do to position themselves for success.
Jean-Marie Vallet Member Angel Investor LaunchPad Venture Group
Jean-Marie is a life sciences entrepreneur and investor, with over 30 years of experience in the pharma/biotech industry including research and development, licensing, strategic planning, corporate M&A, and international sales. In addition to his industry roles, Jean-Marie is an advisor to the French government on trade. He has been a member of LaunchPad Venture Group, the largest group of angel investors in New England, for nearly 7 years.
Eugene Wan Associate The Engine
Eugene has used his career to help early stage founders, both as an operator and an investor. Most recently, he served as chief of staff at Galvanize, helping grow the company through a period of national expansion. Before that, he spent time at Foundry Group and Techstars learning the trade of venture. Eugene holds degrees in economics and political Science from the University of Colorado-Boulder.
Todd Woodworth Aanalyst BioInnovation Capital
Todd is an Analyst with BioInnovation Capital and has been with the firm since inception. Todd supports the partners of the firm with company sourcing, evaluation and analysis. Prior to BioInnovation Capital, Todd held business development roles at MedChem Partners and graduated with a bachelors degree in chemistry from Hamilton College.